MSC vs exosomes for Arterial Hypertension: what the registries show
For Arterial Hypertension, the registry holds 11 MSC records against 8 exosomes records. MSC carries the larger research programme; neither column is a head-to-head efficacy result. Snapshot 2026-08-29.
Side by side
| Metric | MSC | exosomes |
|---|---|---|
| Registered studies | 11 | 8 |
| Recruiting now | 2 | 2 |
| Phase 3 or 4 records | 0 | 0 |
| Completed | 6 | 6 |
| Stopped early | 0 | 0 |
| Countries with sites | 8 | 5 |
| Median planned enrolment | 51 | 73 |
| First registration year | 2,012 | 2,016 |
The condition underneath the comparison
Resistant hypertension is a plumbing-and-signalling problem: vascular stiffness, renal sodium handling and sympathetic tone. Cell approaches are studied mostly for endothelial repair and inflammation, usually as an add-on to drugs rather than a replacement. Blood pressure is also the most placebo-responsive vital sign in medicine, which shapes how these trials must be designed.
MSC: what it is
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
exosomes: what it is
Exosome and extracellular-vesicle products are cell-free: vesicles harvested from cultured cells and given without the cells themselves. They are attractive commercially because they avoid live-cell logistics, and they are regulatorily contested for the same reason — several regulators have issued explicit warnings about unapproved exosome products marketed for human use.
Maturity difference
MSC has 0 Phase 3/4 records and 6 completed studies; exosomes has 0 and 6. Where both sit early on the ladder, the honest answer to "which works better" is that registrations cannot tell you.
Leading MSC studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07183384 — MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction | Phase 1, Phase 2 | Recruiting | 80 | Universitas Padjadjaran | 2024-07-01 |
| NCT03011541 — Stem Cell Ophthalmology Treatment Study II | n/a | Recruiting | 500 | MD Stem Cells | 2016-01 |
| NCT07542067 — Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmo | Phase 1, Phase 2 | Completed | 1 | Fundación Neumologica Colombiana | 2024-05-15 |
| NCT04055415 — Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension | Phase 1, Phase 2 | Unknown | 60 | Liaocheng People's Hospital | 2019-08-01 |
| NCT02443961 — Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies | Phase 1 | Completed | 10 | Fundacion para la Investigacion Biomedica del Hospital Unive | 2019-04-02 |
Leading exosomes studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07183384 — MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction | Phase 1, Phase 2 | Recruiting | 80 | Universitas Padjadjaran | 2024-07-01 |
| NCT04154332 — Exosome Cargo From Preeclampsia Patients | n/a | Recruiting | 64 | University of Alabama at Birmingham | 2019-12-02 |
| NCT07224737 — Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma. | n/a | Completed | 230 | City of Hope Medical Center | 2024-06-21 |
| NCT07225452 — An Exosomal miRNA-based Liquid Biopsy for ICC Detection | n/a | Completed | 535 | City of Hope Medical Center | 2024-06-21 |
| NCT04142138 — When the Kidney Reacts to Nutritional Changes | n/a | Completed | 9 | Rockefeller University | 2020-02-22 |
The honest comparison
Head-to-head trials putting these two approaches in the same protocol are rare or absent for most conditions. Comparing counts from separate registry queries shows where research effort went — driven by cost, regulation and sponsor interest as much as by biology. Anyone presenting one column of this table as proof of superiority is overreading it.
Frequently asked
Is MSC better than exosomes for Arterial Hypertension?
The registries cannot answer that. They show research volume and maturity, not comparative effectiveness: 11 vs 8 registered records (2026-08-29).
Which has more late-stage research for Arterial Hypertension?
MSC: 0 Phase 3/4 records. exosomes: 0.
Can a clinic offer both?
Some do, which is itself worth questioning — a provider offering every modality for every condition is describing a business model, not a treatment rationale.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.